Key takeaway
DOZA has never sold Biopatid. Public statement of 13 Sep 2026: branded-analog risks were disclosed earlier; after the State Medicines Service ban (batch 9922) and the SBU case, catalog URLs redirect here (301). We recommend Mounjaro (Eli Lilly) and Ozempic (Novo Nordisk).
DOZA has never sold Biopatid
Biopatid is a third-party branded analog. Before the scandal we publicly warned about risks: not Eli Lilly, not in Ukraine’s medicines register, no own clinical trials. After the January 2026 ban and the September 2026 SBU case we keep only this informational statement.
Looking for a Biopatid catalog or price?
DOZA has never sold this product. URLs /biopatid/catalog and /biopatid-tsina redirect here (301) so we are not mistaken for a seller. Below: our position, facts, and safer alternatives.
DOZA’s position
Never sold
DOZA has never sold Biopatid and does not sell it now. No cart, offers, or Google Merchant listings for this product.
Warned earlier
On /biopatid and comparison pages we stated openly: not Eli Lilly originator product, Lilly does not supply API to third parties, no Ukraine registration, no own RCTs.
Not part of the scheme
DOZA is not involved in counterfeit manufacture or sale. We distance ourselves from underground schemes and clinics that sold Biopatid.
We recommend originals
For weight-loss programmes — original Mounjaro (Eli Lilly) or Ozempic (Novo Nordisk) with specialist support and a 2–8°C cold chain.
Timeline of facts
- 16 January 2026
Ukraine’s State Medicines Service banned circulation of falsified unregistered BIOPATID 60 mg/2 ml, batch 9922 (UNIKKA PHARMA LTDA). It was never officially imported.
State Medicines Service order No. 20-001.3/002.0/17-26 → - 13 September 2026
Prosecutors and the Security Service of Ukraine announced a large scheme of illegal manufacture and sale of counterfeit Biopatid: 27 suspects, 250+ searches.
Office of the Prosecutor General → - 13 September 2026
DOZA publishes this statement and keeps /biopatid as an informational page. Catalog URLs redirect here (301) to avoid a false commercial association.
Sources: official State Medicines Service and Prosecutor General / SBU notices. We do not publish names of case defendants.
What we published before the scandal
These points were already on the DOZA site before Jan–Sep 2026 — that is our transparency:
Biopatid is not an original medication. The tirzepatide molecule was developed by Eli Lilly (Mounjaro, Zepbound). Biopatid is manufactured by UNIKKA PHARMA (LCA Farmacêutica LTDA, Brazil) — a third-party company not affiliated with Eli Lilly.
Eli Lilly's position: Eli Lilly officially states that it does not supply the active pharmaceutical ingredient (API) tirzepatide to any third-party manufacturers.
No registration: Biopatid is not registered in the State Register of Medicines of Ukraine. No product containing tirzepatide as an active ingredient is registered in Ukraine as of 2026.
No proprietary clinical trials: Biopatid has not undergone randomized clinical trials (RCTs). Efficacy data references SURMOUNT-1 — a study conducted by Eli Lilly for the original Mounjaro.
DOZA provides full transparency regarding product origin. Consult with your physician. Full analysis on the clinical research page →
What to choose instead of risky analogs
Original medicines with a known molecule, clinical evidence, and controlled 2–8°C logistics.
FAQ
No. DOZA has never sold Biopatid and does not offer it now. This page is an informational statement about risks and official facts.
Valentyna Tytorenko
Diploma-certified endocrinologist, certified dietitian and nutritionist
